Year All2024202320222021202020192018201720162015201420132012201120102007 03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease WALTHAM, Mass. , March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More 03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGAVE-201 trial of axatilimab in cGVHD - - End of year cash balance of $293.1 million provides cash runway into 2023- - Company to host Read More 03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 Read More 02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index WALTHAM, Mass. , Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the Read More 12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More 12.07.20 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More 12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD - Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents - - Enrollment in pivotal AGAVE-201 trial on track to start by year-end - - Company to host conference call Read More 11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring Read More 11.11.20 Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting - Response rate of ~60% observed in patients following a median of five prior lines of treatment - - Company to host conference call and webcast following oral presentation on Sunday, December 6, 2020 - WALTHAM, Mass. , Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More
03.31.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease WALTHAM, Mass. , March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
03.08.21 Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGAVE-201 trial of axatilimab in cGVHD - - End of year cash balance of $293.1 million provides cash runway into 2023- - Company to host Read More
03.01.21 Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 Read More
02.24.21 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
12.18.20 Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index WALTHAM, Mass. , Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the Read More
12.11.20 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass , Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.09.20 Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass. , Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of Read More
12.07.20 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More
12.06.20 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD - Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents - - Enrollment in pivotal AGAVE-201 trial on track to start by year-end - - Company to host conference call Read More
11.30.20 Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring Read More
11.11.20 Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting - Response rate of ~60% observed in patients following a median of five prior lines of treatment - - Company to host conference call and webcast following oral presentation on Sunday, December 6, 2020 - WALTHAM, Mass. , Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More